University Health Network, Toronto, Canada.
Credit Valley Hospital, Mississauga; London Health Sciences Centre, London; National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston; Burlington Urology, Burlington, Ontario; Prostate Cancer Centre; University of Calgary, Calgary, Alberta; McGill University Health Centre, Montreal; Hotel Dieu de Quebec, Quebec City, Quebec; and the University of British Colombia, Vancouver, British Colombia, Canada.
High-grade prostatic intraepithelial neoplasia (HGPIN) is a putative precursor of invasive prostate cancer (PCa). Preclinical evidence suggests vitamin E, selenium, and soy protein may prevent progression of HGPIN to PCa. This hypothesis was tested in a randomized phase III double-blind study of daily soy (40 g), vitamin E (800 U), and selenium (200 μg) versus placebo.
Three hundred three men in 12 Canadian centers were analyzed. The main eligibility criterion was confirmed HGPIN in at least one of two biopsies within 18 months of random assignment. Treatment was administered daily for 3 years. Follow-up prostate biopsies occurred at 6, 12, 24, and 36 months postrandomization. The primary end point was time to development of invasive PCa. Kaplan-Meier plots and log-rank tests were used to compare two treatment groups for this end point.
For all patients, the median age was 62.8 years. The median baseline prostate-specific antigen (PSA; n = 302) was 5.41 ug/L; total testosterone (n = 291) was 13.4 nmol/L. Invasive PCa developed among 26.4% of patients. The hazard ratio for the nutritional supplement to prevent PCa was 1.03 (95% CI, 0.67 to 1.60; P = .88). Gleason score distribution was similar in both groups with 83.5% of cancers graded Gleason sum of 6. Baseline age, weight, PSA, and testosterone did not predict for development of PCa. The supplement was well tolerated with flatulence reported more frequently (27% v 17%) among men receiving micronutrients.
This trial does not support the hypothesis that combination vitamin E, selenium, and soy prevents progression from HGPIN to PCa.
Written by:
Fleshner NE, Kapusta L, Donnelly B, Tanguay S, Chin J, Hersey K, Farley A, Jansz K, Siemens DR, Trpkov K, Lacombe L, Gleave M, Tu D, Parulekar WR. Are you the author?
Reference: J Clin Oncol. 2011 May 2. Epub ahead of print.
doi: 10.1200/JCO.2010.32.0994
PubMed Abstract
PMID: 21537051
UroToday.com Prostate Cancer Section
